VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
Stock Information for VBI Vaccines Inc.
Loading
Please wait while we load your information from QuoteMedia.